Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection (Q96124007)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

title

Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

1 reference

Thomas D Norton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Takuya Tada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Rebecca Leibowitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Verena van der Heide

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Dirk Homann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Nathaniel R Landau

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

20 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32497512%20AND%20SRC:MED&resulttype=core&format=json

Dendritic cell-based immunotherapy: a basic review and recent advances.

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Dendritic cell based vaccines for HIV infection: the way ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Pembrolizumab versus Ipilimumab in Advanced Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Restoring function in exhausted CD8 T cells during chronic viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Role of PD-1 during effector CD8 T cell differentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Lentivirally transduced dendritic cells as a tool for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2020.05.018